|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
09939 KINTOR PHARMA-B
Nominal 
1.200 +0.100 (+9.091%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 5,000 | -- | 0 | 0 | 34,231 | 0 |
| Cost of Sales | (9,730) | -76.959% | (42,229) | -- | -- | -- |
| Gross Profit | (4,730) | -88.799% | (42,229) | -- | -- | -- |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (1,206) | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (1,429) | -- | 52 | (568) | 0 | 0 | |
| Profit / (Loss) before Taxation | (155,274) | -85.473% | (1,068,861) | (953,284) | (842,095) | (508,228) | |
| Taxation | (18) | -- | 8,041 | (1,085) | 0 | (73) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (155,292) | -85.361% | (1,060,820) | (954,369) | (842,095) | (508,301) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 9,277 | -- | (3,387) | 1,305 | (9,555) | (7,040) |
| Depreciation & Amortisation | 17,627 | -7.109% | 18,976 | 18,388 | 10,510 | 6,501 |
| Directors' Emoluments | -- | -- | 27,362 | 18,573 | 6,570 | 4,754 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified (Modified Report) | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -36.000 | -85.425% | -247.000 | -253.000 | -236.000 | -164.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.903) | (2.553) | (2.950) | (1.231) |
| NBV per share ($) | 0.657 | -- | 1.024 | 3.341 | 4.270 | 4.082 |
| Remarks: | Real time quote last updated: 22/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -155,292,000 |
| %Change | -85.361% |
| EPS / (LPS) | RMB -0.360 |
| NBV Per Share (¥) | RMB 0.657 |